Podcast Summary: Becker Business

Episode: Market Trends and Investor Opportunities in Healthcare with Holly Buckley of McGuireWoods LLP
Date: September 3, 2025
Host: Scott Becker
Guest: Holly Buckley (Chair, Healthcare Department, McGuireWoods LLP)

Episode Overview

In this engaging conversation, Scott Becker sits down with Holly Buckley, a leading healthcare attorney and policy influencer, to discuss the most pressing trends affecting private equity (PE) and investment in the healthcare sector. Holly brings her experience at the nexus of healthcare law and PE, offering actionable insights on investor behavior, regulatory dynamics, manufacturing reshoring, and deal market activity.

Key Discussion Points & Insights

1. Surge in Onshoring Fueled by Private Equity

[01:02 - 02:30]

• Trend: Holly highlights a recent "onshoring wave" in contract manufacturing, largely driven by private equity. There's been accelerated consolidation and investment in domestic pharmaceutical and biotech manufacturing facilities.
• Drivers: Increased demand for faster delivery, lower costs, and resilient domestic supply chains are key motivators.
• Quote:

  “Private capital is strategically placing bets on resilient domestic supply chains ready to scale manufacturing capacity.”
  — Holly Buckley [01:32]

• Risks: Holly notes ongoing risks tied to the political environment, as future policy shifts could impact the economic viability of these investments.

2. Uncertainty After CDC/FDA Shakeups and Vaccine Policy Changes

[02:30 - 05:18]

• Events: Holly reviews major leadership changes at the CDC, including the abrupt firing of the director and resignations by senior scientists, alongside FDA moves to restrict updated COVID vaccine access.
• Market Impact: The resulting uncertainty is creating nervousness for investors around vaccine R&D, availability, and distribution chains—potentially opening doors for private sector solutions in data analytics, laboratory services, and infrastructure.
• Quote:

  “I think there’s also going to be likely a less centralized federal approach to vaccines and public health, which may create opportunities in the private sector...”
  — Holly Buckley [04:27]

• Open Questions: The future landscape is unclear as policy and public health direction remain unsettled.

3. Revocation of the Federal Competition Executive Order

[04:57 - 05:22]

• Policy Shift: The Biden-era executive order demanding stricter antitrust scrutiny (including in healthcare) has been revoked.
• Possible Effects: While the FTC and DOJ still call for aggressive enforcement, Holly forecasts that healthcare M&A may face somewhat less regulatory friction, creating a more favorable climate for deals—even if not fully reverting to a hands-off stance.
• Quote:

  “...likely to see a less regulated sector than there would have been in the last year or two.”
  — Holly Buckley [05:17]

4. Onshoring Sustainability and Investor Dilemmas

[05:22 - 06:43]

• Host Analysis: Scott questions if onshoring will last or simply reflect the current administration’s trend, raising concerns about making large, irreversible capital investments amid policy uncertainty.
• Holly's Response: She emphasizes that bipartisan support for onshoring makes policy reversal unlikely, but cautions that any new incentives to offshore could threaten these investments.
• Quote:

  “Big capital investments become very problematic if the economics aren’t there to support them on a go forward basis.”
  — Holly Buckley [06:38]

5. Deal Market Activity and Private Equity Exits

[06:43 - 07:37]

• Current Activity: Despite ongoing challenges for large PE funds in completing exits, Holly notes an encouraging increase in deal volume, both in large transactions and roll-ups, since the start of the year’s second half.
• Quote:

  “We’ve seen a big uptick... This has kind of been the speed up and the pickup that we’ve been waiting for and we seem to be in it right now.”
  — Holly Buckley [07:14]

Notable Quotes & Memorable Moments

• Reshoring as a Major Investment Trend:
  “It’s super interesting. And this is drugs and bio stimulants and such that are being manufactured now in the US versus overseas.”
  — Holly Buckley [01:59]

• On Changes in Vaccine Access:
  “On the same day the FDA limited its updated COVID-19 vaccines to high risk groups... news around how big pharmacies are going to deal with this and the availability of drugs and things like that.”
  — Holly Buckley [02:55]

• On the Investment Outlook Amid Policy Volatility:
  “If people make big investments on capital projects onshore, it would be very unpopular for policy to come along that then made it very difficult for that to continue.”
  — Holly Buckley [05:57]

Timestamps for Key Segments

• [01:02] – Holly Buckley introduces the onshoring trend and PE’s role
• [02:30] – Discussion of CDC/FDA shakeups and impacts on vaccine markets
• [04:57] – Executive order revocation and implications for healthcare M&A
• [05:22] – Scott and Holly debate the durability of onshoring investments
• [06:43] – Private equity exits and current deal market environment

Summary Flow & Tone

The discussion is fast-paced, candid, and analytical, drawing on up-to-the-minute policy shifts, deal activity, and market sentiment. Holly Buckley’s perspectives are practical and cautiously optimistic, balancing current enthusiasm with realism about regulatory and political uncertainty. Scott Becker’s probing questions add industry context, helping listeners grasp complex market dynamics in a down-to-earth, conversational style.

For investors and industry watchers, this episode spotlights the interconnected challenges—and new opportunities—shaping healthcare investment as 2025 unfolds.